<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002792</url>
  </required_header>
  <id_info>
    <org_study_id>1032.01</org_study_id>
    <secondary_id>FHCRC-1032.01</secondary_id>
    <secondary_id>NCI-H96-0929</secondary_id>
    <secondary_id>CDR0000064859</secondary_id>
    <nct_id>NCT00002792</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders</brief_title>
  <official_title>ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining bone marrow or peripheral stem cell transplantation with
      chemotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more
      tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus either
      bone marrow or peripheral stem cell transplantation in treating patients with
      myeloproliferative disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Assess disease free survival in patients with idiopathic myelofibrosis treated with a
           preparative busulfan/cyclophosphamide regimen followed by allogeneic bone marrow or
           peripheral blood stem cell transplantation.

        -  Determine the risk of primary graft failure in these patients.

      OUTLINE: Patients receive a preparative regimen consisting of oral busulfan every 6 hours on
      days -7 through -4 and cyclophosphamide on days -3 and -2. Patients then receive allogeneic
      bone marrow or peripheral blood stem cells on day 0. Patients registered on protocol
      FHCRC-1106.00 randomized to stem cell transplant receive unmodified G-CSF-mobilized stem
      cells from an HLA-identical donor.

      Patients receive cyclosporine/methotrexate or tacrolimus/methotrexate as prophylaxis for
      graft-versus-host disease (GVHD). Patients receiving marrow from unrelated donors are
      eligible for appropriate GVHD prophylaxis studies.

      Patients are followed at 6 and 12 months after transplant.

      PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study over approximately
      3.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Idiopathic myelofibrosis (IMF) with at least 1 poor prognosis characteristic,
             including but not limited to:

               -  Hemoglobin less than 10 g/dL

               -  Platelet count less than 100,000/mm^3

               -  Hepatomegaly (i.e., palpable liver edge 5 cm below costal margin)

               -  Clinical requirement for splenectomy

          -  Other myeloproliferative disorders in an IMF like myelofibrotic state eligible

          -  No evidence of leukemic progression, e.g.:

               -  Greater than 15% peripheral blood blasts

               -  Fever or bone pain of unknown origin

               -  Rapidly progressing splenomegaly

          -  No other causes for myelofibrosis, such as:

               -  Collagen vascular disorder

               -  Lymphoma

               -  Granulomatous infection

               -  Metastatic carcinoma

               -  Hairy cell leukemia

               -  Myelodysplastic syndrome

          -  No active central nervous system disease

          -  One of the following donor/patient pairings is required:

               -  Donor status:

                    -  Genotypic or phenotypic HLA-matched relative

                         -  Maximum patient age of 65

                    -  One antigen HLA-mismatched relative, HLA-matched unrelated donor, or one
                       antigen HLA-mismatched unrelated donor

                         -  Maximum patient age of 55

          -  Transplant on this protocol allowed for patients registered on protocol FHCRC-1106.00

        PATIENT CHARACTERISTICS:

        Age:

          -  65 and under

        Performance status:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

        Hepatic:

          -  Bilirubin no greater than 2 times normal

          -  SGPT no greater than 4 times normal

        Renal:

          -  Creatinine no greater than two times normal OR

          -  Creatinine clearance at least 50%

        Cardiovascular:

          -  Ejection fraction at least 50%

          -  Cardiac evaluation required if signs or symptoms of coronary artery disease or
             congestive heart failure

        Other:

          -  HIV negative

          -  No active infection

          -  Patients excluded from this protocol are referred to protocol FHCRC-179.05

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Joachim Deeg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997 Sep;98(4):1010-6.</citation>
    <PMID>9326205</PMID>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <keyword>polycythemia vera</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

